The guidance withdrawal is the most significant signal — it removes the forward anchor for the stock and implies management sees material downside risk to prior expectations. With cash burning rapidly ($20.4M in H1 2026) and the company still deeply unprofitable, watch for a potential capital raise or restructuring announcement in the coming months. The new CEO's strategic review could lead to asset sales or a reverse merger.
Price Chart
Executive Summary
TELA Bio reported Q2 2026 revenue of $19.3M, a 4% decline YoY, and an EPS of -$0.20, missing consensus estimates of -$0.18. The company withdrew its full-year 2026 revenue guidance, citing a decline in OviTex PRS volumes and ongoing price/mix headwinds. A new CEO was appointed, but the guidance withdrawal and revenue miss signal significant near-term uncertainty and deteriorating fundamentals for this $39M market-cap medical device company.
Key Financial Metrics
Key Facts
- Revenue declined 4% YoY to $19.3M, missing consensus of $20.0M
- EPS of -$0.20 missed consensus of -$0.18 (-12.4% miss)
- Full-year 2026 revenue guidance withdrawn, citing OviTex PRS volume decline and competitive bundling pressures
- Net loss widened to $11.3M from $9.9M in the prior-year quarter
- Cash burn continues: cash dropped to $30.4M from $50.8M at year-end 2025
- New CEO Heather Getz appointed August 4, 2026, signaling a strategic review
Financial Impact
Revenue miss of ~$0.7M vs consensus; guidance withdrawal removes forward visibility for a $39M market-cap company
Risk Factors
- Further revenue deterioration in H2 2026 as OviTex PRS headwinds persist
- Cash runway concern: $30.4M at current burn rate (~$11M/quarter) provides ~9 months of liquidity
- Potential dilutive equity offering to extend runway
- Competitive bundling from larger players could continue pressuring market share and pricing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-093371 |
| Document: tm2622768d1_8k.htm | 0001104659-26-093371 |
| Document: 0001104659-26-093371-index-headers.html | 0001104659-26-093371 |
| Document: 0001104659-26-093371-index.html | 0001104659-26-093371 |
| Document: 0001104659-26-093371.txt | 0001104659-26-093371 |
| 8-K Data (Synthetic) | 0001104659-26-093371 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $0.7380 $1.24 | ▲ +68.02% | ▲ +68.21% | $1.19 (+61.25%) |
Aug 10, 2026 7w ago | 8-K | $0.7900 $0.9113 | ▼ −15.35% | ▼ −16.41% | $1.19 (−50.63%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.19 (+38.37%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.19 (+38.37%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.19 (+38.37%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.19 (+38.37%) |
May 12, 2026 20w ago | 8-K | $0.9600 $0.9120 | ▼ −5.00% | ▼ −4.39% | $1.19 (+23.96%) |
May 12, 2026 20w ago | Press Release | $0.9600 $0.9120 | ▲ +5.00% | ▲ +4.39% | $1.19 (−23.96%) |
Apr 30, 2026 22w ago | 8-K | $0.9890 $0.9000 | ▼ −9.00% | ▼ −14.28% | $1.19 (+20.32%) |
Apr 21, 2026 23w ago | Press Release | $0.6250 $0.8600 | ▲ +37.60% | ▲ +34.43% | $1.19 (+90.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access